CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer
dc.contributor.buuauthor | Tunca, Berrin | |
dc.contributor.buuauthor | Egeli, Ünal | |
dc.contributor.buuauthor | Çeçener, Gülşah | |
dc.contributor.buuauthor | Tezcan, Gülçin | |
dc.contributor.buuauthor | Gökgöz, Şehsuvar | |
dc.contributor.buuauthor | Taşdelen, İsmet | |
dc.contributor.buuauthor | Bayram, Nuran | |
dc.contributor.buuauthor | Tolunay, Şahsine | |
dc.contributor.buuauthor | Umut, Görkem | |
dc.contributor.buuauthor | Demirdöğen, Elif | |
dc.contributor.buuauthor | Ertürk, Elif | |
dc.contributor.buuauthor | Ak, Seçil | |
dc.contributor.buuauthor | Çetintaş, Sibel | |
dc.contributor.buuauthor | Evrensel, Türkkan | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/İktisadi ve İdari Bilimler Fakültesi/Ekonometri Bölümü. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0001-5492-184X | tr_TR |
dc.contributor.orcid | 0000-0002-9732-5340 | tr_TR |
dc.contributor.orcid | 0000-0002-3820-424X | tr_TR |
dc.contributor.orcid | 0000-0001-7904-883X | tr_TR |
dc.contributor.orcid | 0000-0002-1619-6680 | tr_TR |
dc.contributor.orcid | 0000-0002-5956-8755 | tr_TR |
dc.contributor.orcid | 0000-0002-9038-0515 | tr_TR |
dc.contributor.orcid | 0000-0002-4483-9284 | tr_TR |
dc.contributor.researcherid | AAG-9068-2021 | tr_TR |
dc.contributor.researcherid | AAA-7047-2020 | tr_TR |
dc.contributor.researcherid | AAH-3843-2020 | tr_TR |
dc.contributor.researcherid | AAJ-1027-2021 | tr_TR |
dc.contributor.researcherid | AAP-9988-2020 | tr_TR |
dc.contributor.researcherid | AAH-1420-2021 | tr_TR |
dc.contributor.researcherid | ABI-6078-2020 | tr_TR |
dc.contributor.researcherid | AAI-1612-2021 | tr_TR |
dc.contributor.researcherid | F-8554-2017 | tr_TR |
dc.contributor.scopusid | 6602965754 | tr_TR |
dc.contributor.scopusid | 55665145000 | tr_TR |
dc.contributor.scopusid | 6508156530 | tr_TR |
dc.contributor.scopusid | 25650627600 | tr_TR |
dc.contributor.scopusid | 6603238737 | tr_TR |
dc.contributor.scopusid | 9637821500 | tr_TR |
dc.contributor.scopusid | 13609585600 | tr_TR |
dc.contributor.scopusid | 6602604390 | tr_TR |
dc.contributor.scopusid | 37058220200 | tr_TR |
dc.contributor.scopusid | 25644460900 | tr_TR |
dc.contributor.scopusid | 50261655300 | tr_TR |
dc.contributor.scopusid | 55253485700 | tr_TR |
dc.contributor.scopusid | 6505881756 | tr_TR |
dc.contributor.scopusid | 6603942124 | tr_TR |
dc.date.accessioned | 2022-10-03T06:28:28Z | |
dc.date.available | 2022-10-03T06:28:28Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Aims and background. The major cause of death in breast cancer patients is metastasis. Various biomarkers have been used for the early detection of circulating tumor cells in the peripheral blood of breast cancer patients. The aims of the current study were to analyze circulating tumor cells in the blood of breast cancer patients by investigating EGFR, CK19, CK20 and HER2 expression profiles and to evaluate their prognostic importance. Methods. CK19, CK20 and EGFR gene expression profiles were evaluated in the blood samples of 84 female patients with primary invasive ductal breast cancer and 20 healthy female volunteers using SYBR green-based real-time qPCR assays. HER2 expression analyses were conducted in 46 patients who had an HER2-positive primary tumor and in 30 healthy women to determine the cutoff level of positivity. Results. The positive rates of CK20, EGFR, CK19 and HER2 mRNA expression in the peripheral blood were 28.57% (24/84), 20.23% (17/84), 5.95% (5/84) and 2.17% (1/46), respectively. The high positive ratio of CK20 mRNA expression in the peripheral blood of breast cancer was identified for the first time in the current study. Significant differences were identified in CK20 expression status and several clinical parameters related with aggressiveness of tumors using a binary logistic regression analysis. Higher CK20-positive levels were observed in patients who had lymph node metastasis and advanced-grade primary tumors, which were estrogen receptor-negative. We have demonstrated that CK20 may be a novel biomarker that is useful to identify circulating tumor cells and predict breast cancer progression. Conclusions. The results suggest that the investigation of CK20 mRNA with other biomarkers in the peripheral blood of breast cancer patients may be useful to monitor the presence of disseminated tumor cells in the blood circulation and to predict the prognosis of breast cancer. | en_US |
dc.identifier.citation | Tunca, B. vd. (2012). "CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer". Tumori Journal, 98(2), 243-251. | en_US |
dc.identifier.endpage | 251 | tr_TR |
dc.identifier.issn | 0300-8916 | |
dc.identifier.issn | 2038-2529 | |
dc.identifier.issue | 2 | tr_TR |
dc.identifier.pubmed | 22677992 | tr_TR |
dc.identifier.scopus | 2-s2.0-84864881515 | tr_TR |
dc.identifier.startpage | 243 | tr_TR |
dc.identifier.uri | https://doi.org/10.1177/030089161209800211 | |
dc.identifier.uri | https://journals.sagepub.com/doi/10.1177/030089161209800211 | |
dc.identifier.uri | http://hdl.handle.net/11452/28913 | |
dc.identifier.volume | 98 | tr_TR |
dc.identifier.wos | 000305546600011 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications | en_US |
dc.relation.journal | Tumori Journal | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | Circulating tumor cells | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Rna-positive cells | en_US |
dc.subject | Polymerase-chain-reaction | en_US |
dc.subject | Mammaglobin messenger-rna | en_US |
dc.subject | Transcription-pcr assay | en_US |
dc.subject | Peripheral-blood | en_US |
dc.subject | Colorectal-cancer | en_US |
dc.subject | Molecular-detection | en_US |
dc.subject | Prognostic value | en_US |
dc.subject | Rt-pcr | en_US |
dc.subject | Adjuvant chemotherapy | en_US |
dc.subject.emtree | Cytokeratin 19 | en_US |
dc.subject.emtree | Cytokeratin 20 | en_US |
dc.subject.emtree | Epidermal growth factor receptor | en_US |
dc.subject.emtree | Epidermal growth factor receptor 2 | en_US |
dc.subject.emtree | Messenger rna | en_US |
dc.subject.emtree | Tumor marker | en_US |
dc.subject.emtree | ERBB2 protein | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Advanced cancer | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Blood sampling | en_US |
dc.subject.emtree | Breast carcinoma | en_US |
dc.subject.emtree | Cancer prognosis | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Cytokeratin 19 gene | en_US |
dc.subject.emtree | Cytokeratin 20 gene | en_US |
dc.subject.emtree | Epidermal growth factor receptor gene | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gene expression profiling | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | Lymph node metastasis | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Oncogene | en_US |
dc.subject.emtree | Oncogene neu | en_US |
dc.subject.emtree | Primary tumor | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Real time polymerase chain reaction | en_US |
dc.subject.emtree | Tumor cell | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Breast tumor | en_US |
dc.subject.emtree | Cancer grading | en_US |
dc.subject.emtree | Cancer staging | en_US |
dc.subject.emtree | Chemistry | en_US |
dc.subject.emtree | Disease free survival | en_US |
dc.subject.emtree | Early diagnosis | en_US |
dc.subject.emtree | Gene expression regulation | en_US |
dc.subject.emtree | Genetics | en_US |
dc.subject.emtree | Lymph node metastasis | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Paget nipple disease | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Predictive value | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Receiver operating characteristic | en_US |
dc.subject.emtree | Risk | en_US |
dc.subject.emtree | Sensitivity and specificity | en_US |
dc.subject.emtree | Statistical model | en_US |
dc.subject.emtree | Tumor embolism | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Breast neoplasms | en_US |
dc.subject.mesh | Carcinoma, ductal, breast | en_US |
dc.subject.mesh | Disease-free survival | en_US |
dc.subject.mesh | Early detection of cancer | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gene expression profiling | en_US |
dc.subject.mesh | Gene expression regulation, neoplastic | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Keratin-19 | en_US |
dc.subject.mesh | Keratin-20 | en_US |
dc.subject.mesh | Logistic models | en_US |
dc.subject.mesh | Lymphatic metastasis | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Neoplasm grading | en_US |
dc.subject.mesh | Neoplasm staging | en_US |
dc.subject.mesh | Neoplastic cells, circulating | en_US |
dc.subject.mesh | Odds ratio | en_US |
dc.subject.mesh | Predictive value of tests | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Real-time polymerase chain reaction | en_US |
dc.subject.mesh | Receptor, epidermal growth factor | en_US |
dc.subject.mesh | Receptor, erbB-2 | tr_TR |
dc.subject.mesh | Rna, messenger | tr_TR |
dc.subject.mesh | Roc curve | en_US |
dc.subject.mesh | Sensitivity and specificity | en_US |
dc.subject.mesh | Tumor markers, biological | en_US |
dc.subject.scopus | Circulating Neoplastic Cells; Liquid Biopsy; Circulating Tumor DNA | en_US |
dc.subject.wos | Oncology | en_US |
dc.title | CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer | en_US |
dc.type | Article |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: